Silence Therapeutics PLC (LON:SLN) saw its shares rise today on news it has been granted a US patent, which it believes significantly strengthens its claim to ownership of technology used in competitors’ late stage drugs.
The award covers the innovative chemical modification technology pioneered by Silence.
In afternoon trading, Silence shares were up nearly 3% at 210p.
The AIM-listed biotech, which specialises in RNA interference (RNAi), a cellular process of silencing unwanted or harmful genes, believes it could have implications for competitor Alnylam Pharmaceuticals' Patisiran drug.
Key to new treatment?
A treatment for a rare condition called TTR-mediated Amyloidosis (which leads to a protein build up in the body), Patisiran performed positively in a phase III clinical trial.
“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio,” said Silence chief executive Ali Mortazavi.
“This includes Patisiran, which is currently the most advanced RNAi drug in clinical development and has recently shown positive top line phase III results.
“We are highly encouraged by this field-validating event and excited for the prospects of patients living with ATTR."
Analysts said they expect today’s announcement to further assure shareholders of Silence’s ongoing focus on protecting its patent estate and, if proven, lead to potential revenues through licences under the patent portfolio.
-- Adds share price, analyst comment ..